Parmax Pharma Ltd Stock Price Today (NSE: PARMAX)

Parmax Pharma Ltd

136.40+0.00 (+0.00%)
Market Closed

Fundamental Score

...

Parmax Pharma Ltd Share Price — Live NSE/BSE Price, Fundamentals & Analysis

Parmax Pharma Ltd share price today is 136.40, up +0.00% on NSE/BSE as of 22 September 2026. Parmax Pharma Ltd (PARMAX) is a Small-cap company in the Pharmaceuticals sector with a market capitalisation of 51.03 (Cr). The 52-week high for PARMAX share price is 136.40 and the 52-week low is 22.60.

Parmax Pharma Ltd Share Price Chart — NSE/BSE Historical Performance

No data
High
136.40
Low
106.00
Volume
4.7K
Change
+25.29%

Parmax Pharma Ltd share price chart: 25.29% return over the past month. 52-week high ₹136.40, 52-week low ₹22.60.

Parmax Pharma Ltd — Last 10 Trading Days

DateOpenHighLowCloseVolume
136.40136.40136.40136.403.92K (Cr)
135.05135.05135.00135.056.33K (Cr)
133.75133.75133.75133.752.02K (Cr)
131.15131.15131.15131.150.00 (Cr)
131.15131.15131.15131.150.00 (Cr)
131.15131.15131.15131.150.00 (Cr)
131.15131.15131.15131.1555.00K (Cr)
129.90129.90129.90129.90204.00 (Cr)
127.40127.40126.80127.405.18K (Cr)
124.95124.95124.95124.951.28K (Cr)

Parmax Pharma Ltd — Last 12 Months Price History

MonthOpenHighLowCloseChange
133.75136.40133.75136.40+1.98%
102.70131.1598.65131.15+27.70%
79.67111.2779.67104.78+31.52%
37.0378.1137.0078.11+110.94%
33.5043.0031.0037.03+10.54%
31.9035.9327.4530.02-5.89%
29.0032.9722.6028.44-1.93%
34.7139.9929.0030.20-12.99%
33.6642.0028.4036.85+9.48%
35.4935.8929.0833.83-4.68%
35.1935.9928.0035.49+0.85%
31.3335.6829.3034.37+9.70%

Returns & Performance

Return on Equity (ROE)

N/A

Profit generated per ₹1 of shareholder equity

Poor

Return on Capital (ROCE)

-83.10%

Returns generated on total capital deployed

Poor

Oper. Profit Margin (5Y Avg)

-2.27%

Average operating profit margin over 5 years

Dividend Yield

0.00%

Annual dividend as % of current share price

Parmax Pharma Ltd Valuation Check

Price to Earnings (P/E)

N/A

Share price ÷ earnings per share. Lower = cheaper

Poor

Industry Avg P/E

34.89x

Average P/E of all peers in this sector

Market-cap Classification
Small-cap
Higher growth potential with higher volatility.

Shareholding Pattern

Excellent

Promoter Holding

30.80%

% shares held by company founders/management

Poor

FII Holding

0.00%

% shares held by foreign institutional investors

Poor

DII Holding

0.00%

% held by domestic mutual funds, LIC, banks

Excellent

Promoter Pledged %

0.00%

% of promoter shares pledged as collateral — lower is safer

Growth Engine

Excellent

Profit Growth (Quarterly YoY)

387.77%

Net profit growth vs same quarter last year

Excellent

Revenue Growth (Quarterly YoY)

323.21%

Revenue growth vs same quarter last year

Poor

Revenue Growth (5-Year CAGR)

-14.28%

Compounded annual revenue growth over 5 years

EPS Growth (5-Year CAGR)

N/A

Earnings per share growth over 5 years

Net Profit Growth (5-Year CAGR)

N/A

Compounded annual net profit growth over 5 years

Balance Sheet Health

Debt to Equity Ratio

N/A

Total debt ÷ equity. Below 0.5 = financially healthy

Poor

Interest Coverage Ratio

-3.71x

EBIT ÷ interest expense. Above 2.5 = can pay interest comfortably

Free Cash Flow (5-Year Total)

-8.10 (Cr)

Cash left after capex over 5 years. Positive = self-funded growth

Labels (e.g., "Excellent", "Good") are peer-based vs industry/sector averages — data-only, not advice

Parmax Pharma Ltd Fundamental Analysis & Valuation Benchmarking

Educational evaluation of PARMAX across key market metrics for learning purposes.

Positive Indicators

3 factors identified

Robust Profit Growth (387.77%)

Observation: Strong year-over-year profit expansion demonstrates business momentum.

Analysis: Profit growth >20% indicates effective execution and market opportunity capture.

Strong Revenue Growth (323.21%)

Observation: Healthy sales growth indicates market demand and execution capability.

Analysis: Revenue growth >15% suggests strong market position and growth potential.

Zero Share Pledging Risk

Observation: No promoter shares pledged as collateral.

Analysis: Absence of share pledging eliminates potential forced-selling pressure.

Risk Factors

7 factors identified

Suboptimal ROCE (-83.10%)

Observation: Returns on capital employed are below expectations.

Analysis: ROCE <10% suggests potential inefficiencies in capital allocation.

Margin Pressure Concerns (-2.27%)

Observation: Operating margins are below industry standards.

Analysis: OPM <5% may indicate pricing pressures or cost management challenges.

Limited Growth History (-14.28% CAGR)

Observation: Below-average 5-year sales growth trajectory.

Analysis: Low sales CAGR may indicate mature markets or limited growth opportunities.

Weak Interest Coverage (-3.71x)

Observation: Limited ability to service debt obligations from earnings.

Analysis: Low interest coverage raises concerns about financial stability.

Liquidity Concerns (Current Ratio: 0.77)

Observation: Current assets may not adequately cover short-term liabilities.

Analysis: Current ratio <1.0 raises working capital concerns.

Negative Free Cash Flow (₹-8.10 Cr over 5Y)

Observation: Cash outflows exceed inflows.

Analysis: Negative FCF requires analysis of capital expenditure cycle.

No Dividend Distribution

Observation: Company does not currently pay dividends to shareholders.

Analysis: Zero dividend yield may indicate growth reinvestment focus or cash flow constraints.

Parmax Pharma Ltd vs Pharmaceuticals Peers

Peer Comparison - Pharmaceuticals

Compare Parmax Pharma Ltd with 10 other companies in the same sector

11 companies
Company Info
Fundamental
Valuation
Profitability
Financial Health
Growth
Dividend
Company
Company name
Score
Bull Run comprehensive fundamental score based on 20+ metrics
Price
Current trading price of the stock
Market Cap
Total value of all shares in the market
P/E
Price per share divided by earnings per share
ROE
Net income divided by shareholder equity
ROCE
Earnings before interest and tax divided by capital employed
Debt/Eq
Total debt divided by total equity
Profit 5Y
Average annual profit growth over 5 years
Sales 5Y
Average annual sales growth over 5 years
Dividend
Annual dividend per share divided by price per share
0/100
136
₹51.03
-83.10%
Poor
-14.28%
Poor
0.00%
66.4/100
1877
₹450228.65
37.2
Average
14.74%
Average
19.31%
Good
0.0
Excellent
31.64%
Excellent
11.78%
Good
0.82%
56.3/100
9426
₹249775.75
85.5
Average
16.19%
Good
20.38%
Excellent
0.0
Excellent
5.29%
Good
8.67%
Good
0.41%
51.4/100
4927
₹166759.24
78.7
Average
27.07%
Excellent
14.09%
Average
1.8
Average
11.56%
Good
11.80%
Good
0.76%
74.1/100
1139
₹113642.26
25.4
Average
19.74%
Good
21.77%
Excellent
0.4
Excellent
18.76%
Excellent
12.45%
Good
0.09%
40.2/100
1370
₹110675.45
32.8
Average
11.82%
Average
15.67%
Good
0.0
Excellent
10.03%
Good
8.01%
Good
0.90%
34.1/100
1926
₹104025.14
95.0
Average
18.19%
Good
21.35%
Excellent
0.5
Excellent
-1.89%
Poor
7.19%
Good
0.13%
24.6/100
1675
₹96391.01
26.2
Average
9.94%
Poor
14.54%
Average
0.2
Excellent
-8.07%
Poor
6.32%
Good
0.26%
83.4/100
2100
₹96017.92
17.4
Average
26.90%
Excellent
31.80%
Excellent
0.3
Excellent
34.39%
Excellent
13.02%
Good
0.72%
41/100
1141
₹95306.90
29.5
Average
11.75%
Average
14.80%
Average
0.2
Excellent
16.54%
Excellent
12.09%
Good
0.65%
61.5/100
2289
₹94539.83
46.3
Average
12.49%
Average
13.56%
Average
0.4
Excellent
10.52%
Good
18.10%
Excellent
0.04%

Parmax Pharma Ltd Quarterly Performance

Latest quarterly metrics for PARMAX — revenue growth and profit growth vs same quarter last year

Revenue Growth (YoY)

323.21%

Latest quarter vs same quarter previous year

Net Profit Growth (YoY)

387.77%

Latest quarter net profit vs same quarter previous year

5-Year Revenue CAGR

-14.28%

Compounded annual revenue growth over 5 years

5-Year Profit CAGR

N/A

Compounded annual net profit growth over 5 years

Parmax Pharma Ltd Technical Indicators

SMA 50, SMA 200, RSI and volume signals for PARMAX — calculated from daily price history

100RSI 14
Overbought — RSI 100

Momentum is strong — price may be stretched. Watch for pullbacks.

SMA 50
101
▲ Price above SMA 50 — Short-term bullish
SMA 200
51
▲ Price above SMA 200 — Long-term uptrend
30-Day Avg Volume
16K shares/day
Average daily traded volume over last 30 trading sessions

Technical indicators are for educational purposes only. Not investment advice.

Parmax Pharma Ltd Financial Statements

Annual income statement, balance sheet and cash flow for Parmax Pharma Ltd (PARMAX) — sourced from NSE/BSE filings.

Financial Results & Statements

Latest quarterly, annual and period-wise financial data for Parmax Pharma Ltd

Loading latest quarterly results...

About PARMAX (Parmax Pharma Ltd)

Parmax Pharma Ltd is a dynamic force in the pharmaceutical landscape, pushing the boundaries of chemical innovation and therapeutic solutions. Established with a vision to contribu...te to the well-being of society, Parmax focuses on the meticulous development and production of essential pharmaceutical ingredients. Situated in the heart of India's industrial hub, the company boasts state-of-the-art manufacturing facilities equipped with cutting-edge technology and staffed by a team of experienced scientists and engineers. Parmax Pharma's unwavering commitment to quality, safety, and environmental responsibility is reflected in its stringent adherence to global regulatory standards. The company's dedication extends beyond mere production; it is dedicated to fostering collaborative partnerships with researchers, healthcare providers, and other stakeholders to drive advancements in medical science. At the core of Parmax Pharma's operations lies a diverse portfolio of bulk drugs, advanced drug intermediates, and specialty chemicals, each meticulously crafted to meet the ever-evolving needs of the pharmaceutical industry. The company leverages its extensive research and development capabilities to formulate innovative products that address critical healthcare challenges. Parmax prioritizes sustainable manufacturing practices, ensuring that its operations are environmentally conscious and minimize their ecological footprint. This commitment to sustainability is deeply ingrained in the company's ethos, demonstrating its responsibility towards future generations. From the sourcing of raw materials to the final product release, Parmax Pharma maintains rigorous quality control measures to ensure the efficacy and safety of its offerings. Parmax Pharma stands as a testament to the power of Indian ingenuity and entrepreneurial spirit. From its humble beginnings, the company has steadily grown into a respected player in the global pharmaceutical market. Its success is built on a foundation of scientific excellence, ethical business practices, and a deep-seated commitment to customer satisfaction. Parmax Pharma's story is not just about manufacturing pharmaceuticals; it is about contributing to a healthier future for people around the world. With a clear vision and unwavering dedication, Parmax Pharma is poised to continue its journey of innovation and growth, solidifying its position as a trusted partner in the pursuit of better health.

Company Details

Symbol:PARMAX
Industry:Pharmaceuticals
Sector:Pharmaceuticals

Key Leadership

Dr. Umang Alkesh Gosalia
MD & Whole Time Director
Mr. Keyur Dinesh Vora
Chief Financial Officer

PARMAX Share Price: Frequently Asked Questions

What is the current share price of Parmax Pharma Ltd?

Parmax Pharma Ltd (PARMAX) trades at ₹136.40 on NSE and BSE. Market cap ₹51.03 (Cr). Educational data only.

What is the P/E ratio of Parmax Pharma Ltd?

Parmax Pharma Ltd has a P/E of N/Ax vs industry average 34.89x.

What is the Bull Run score for Parmax Pharma Ltd?

Parmax Pharma Ltd has a Bull Run score of 0/100 based on 25+ financial parameters.

Does Parmax Pharma Ltd pay dividends?

Parmax Pharma Ltd has a dividend yield of 0.00%. Past dividends don't guarantee future payments.

What is the ROE of Parmax Pharma Ltd?

Parmax Pharma Ltd has ROE of N/A. Higher ROE indicates better use of shareholder equity.

What is the debt-to-equity ratio of Parmax Pharma Ltd?

Parmax Pharma Ltd has debt-to-equity of N/A.

Is Parmax Pharma Ltd a good investment?

Bull Run gives Parmax Pharma Ltd a score of 0/100. This is not investment advice — consult a SEBI-registered advisor.